Sagimet Biosciences (SGMT) CLO awarded 100,000 stock options at $7.27

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Sagimet Biosciences Inc. reported that Chief Legal & Admin. Officer Elizabeth Rozek received a grant of stock options as part of her compensation. She was awarded 100,000 stock options, each giving the right to buy one share of Series A common stock at an exercise price of $7.27 per share. These options expire on May 27, 2036. According to the terms, the shares underlying this option will vest in 48 equal monthly installments beginning after May 28, 2026, contingent on her continued service, and her reported derivative holdings after this grant total 100,000 options.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Rozek Elizabeth

Role Chief Legal & Admin. Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	100,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 100,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Stock options granted: 100,000 options Exercise price: $7.27 per share Expiration date: May 27, 2036 +3 more

6 metrics

Stock options granted 100,000 options Grant to Chief Legal & Admin. Officer on May 28, 2026

Exercise price $7.27 per share Exercise price of granted stock options

Expiration date May 27, 2036 Option term end date

Underlying shares 100,000 shares Series A common stock underlying options

Vesting schedule 48 monthly installments Vesting begins after May 28, 2026, subject to continued service

Derivative holdings after grant 100,000 options Total derivative securities following transaction

Key Terms

Stock Option (Right to Buy), Series A Common Stock, exercise price, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Series A Common Stock financial

"underlying_security_title: Series A Common Stock"

Series A common stock is a specific class of a company’s ordinary shares issued during an early formal funding round, carrying the ownership rights and voting power tied to that class. For investors it signals an early-stage equity claim with potential upside if the business grows, but also greater risk and typically less liquidity than shares in mature, publicly traded firms—imagine buying a seat on a startup’s team before the company has proven itself.

exercise price financial

"conversion_or_exercise_price: 7.2700"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/01/2026 - 09:14 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rozek Elizabeth

(Last)

(First)

(Middle)

SAGIMET BIOSCIENCES INC.

155 BOVET ROAD, SUITE 303

(Street)

SAN MATEO

CALIFORNIA

94402

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sagimet Biosciences Inc. [ SGMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Legal & Admin. Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$7.27	05/28/2026		A		100,000		⁽¹⁾	05/27/2036	Series A Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following May 28, 2026, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Elizabeth Rozek	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Sagimet Biosciences (SGMT) report for Elizabeth Rozek?

Sagimet Biosciences reported that Chief Legal & Admin. Officer Elizabeth Rozek received a grant of 100,000 stock options. These options are a compensation award, not an open-market purchase or sale, and give her the right to buy Series A common stock at a fixed price.

What are the key terms of Elizabeth Rozek’s new stock options at Sagimet Biosciences (SGMT)?

The grant covers 100,000 stock options with an exercise price of $7.27 per share and an expiration date of May 27, 2036. Each option corresponds to one share of Series A common stock under the company’s equity compensation arrangements.

How do the Sagimet Biosciences (SGMT) options granted to Elizabeth Rozek vest?

The shares underlying the 100,000 options vest over 48 equal monthly installments after May 28, 2026. Vesting is conditioned on Elizabeth Rozek’s continued service with Sagimet Biosciences on each applicable monthly vesting date throughout the four-year period.

Did the Sagimet Biosciences (SGMT) Form 4 show any stock sales by Elizabeth Rozek?

The Form 4 shows only a grant of stock options to Elizabeth Rozek and no sales or purchases of common stock. The transaction is coded as an acquisition related to a grant or award, reflecting equity-based compensation rather than an open-market trade.

What is Elizabeth Rozek’s derivative position after this Sagimet Biosciences (SGMT) option grant?

Following the reported transaction, Elizabeth Rozek holds 100,000 derivative securities in the form of stock options. These options relate to Series A common stock, are held directly, and reflect her position as reported immediately after the compensation grant transaction.